Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA

International Journal of Molecular Medicine

Volumn 23, Issue 5, 2009, Pages 651-657

  Ajtay, Zénó ^a   Scalera, Fortunato ^b   Cziráki, Attila ^a   Horváth, Iván ^a   Papp, Lajos ^a   Sulyok, Endre ^a   Szabo, Csaba ^c   Martens Lobenhoffer, Jens ^b   Awiszus, Friedemann ^b   Bode Böger, Stefanie M ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Angiography; L arginine; L arginine asymmetrical dimethylarginine ratio; Risk factor

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; ORNITHINE;

ADULT; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG ELUTING STENT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STENT;

AGED; ARGININE; CARDIOVASCULAR SURGICAL PROCEDURES; CASE-CONTROL STUDIES; CORONARY DISEASE; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; STENTS; TIME FACTORS;

EID: 67649429267     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000176     Document Type: Article

References (37)

1. Böger RH, Sydow K, Borlak J, et al: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethioninedependent methyltransferases. Circ Res 87: 99-105, 2000.
2. Ogawa T, Kimoto M and Sasaoka K: Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264: 10205-10209, 1989.
3. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M and Imaizumi T: Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circ Res 92: 226-233, 2003.
4. Matsuoka H, Itoh S, Kimoto M, et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibtor, in experimental hypertension. Hypertension 29: 242-247, 1997.
5. Vallance P, Leone A, Calver A, Collier J and Moncada S: Accumulation of an endogenous inhibtor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
6. Böger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF and Cooke JP: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction - Its role in hypercholesterolemia. Circulation 98: 1842-1847, 1998.
7. Cooke JP: Asymmetric dimethylarginine - the Über marker? Circulation 109: 1813-1819, 2004.
8. Kielstein JT and Zoccali C: Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46: 186-202, 2005.
9. Hori T, Matsubara T, Ishibashi T, et al: Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasopastic angina. Circ J 67: 305-311, 2003.
10. Schnabel R, Blankenberg S, Lubos E, et al: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Results from the AtheroGene study. Circ Res 97: E53-E59, 2005.
11. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J and Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128, 2001.
12. Bae SW, Stühlinger MC, Yoo HS, et al: Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95: 729-733, 2005.
13. Lu TM, Ding YA, Lin SJ, Lee WS and Tai HC: Plasma levels of asymmetric dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24: 1912-1919, 2003.
14. De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24: 1601-1610, 2003.
15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al: ACC/AHA/SCAI 2005 guideline update for precutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Catheter Cardiovasc Interv 67: 87-112, 2006.
16. Martens-Lobenhoffer J and Bode-Böger SM: Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 42: 488-493, 2006.
17. Martens-Lobenhoffer J, Postel S, Tröger U and Bode-Böger SM: Determination of ornithine, in human plasma by hydrophilic-interaction chromatography-tandem mass spectrometry. J Chromatogr B 855: 271-275, 2007.
18. Suzuki T, Hayase M, Hibi K, et al: Effect of local delivery of L-arginine on in-stent restenosis in human. Am J Cardiol 89: 363-367, 2002.
19. Bode-Böger SM, Scalera F and Ignarro LJ: The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 114: 295-306, 2007.
20. Luque Contreras D, Vagas Robles H, Romo E, Rios A and Escalante B: The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 112: 553-563, 2006.
21. Stone GW, Brodie BR, Griffin JJ, et al: Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial Investigators. J Am Coll Cardiol 31: 23-30, 1998.
22. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329: 1615-1622, 1993.
23. van't Veer M, Pijls NHJ, Aarnoudse W, Koolen JJ and van de Vosse FN: Evaluation of the haemodynamic characteristics of drug-eluting stents at implantation and at follow-up. Eur Heart J 27: 1811-1817, 2006.
24. LaDisa JF Jr, Olson LE, Douglas HA, Warltier DC, Kersten JR and Pagel PS: Alterations in regional vascular geometry produced by theoretical stent implantation influence distributions of wall shear stress: analysis of a curved coronary artery using 3D computational fluid dynamic modeling. Biomed Eng Online 5: 40, 2006.
25. Stone PH, Coskun AU, Kinlay S, et al: Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans. In vivo 6-months follow-up study. Circulation 108: 438-444, 2003.
26. Osanai T, Saitoh M, Sasak S, Tomita H, Matsunaga T and Okumura K: Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 42: 985-990, 2003.
27. Sydow K and Münzel T: ADMA and oxidative stress. Atherosclerosis 4 (Suppl): 41-51, 2003.
28. Scalera F, Martens-Lobenhoffer J, Täger M, Bukowska A, Lendeckel U and Bode-Böger SM: Effect of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophy Res Commun 345: 1075-1082, 2006.
29. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Täger M and Bode-Böger SM: Endogenous nitric oxide synthesis inhibitor asymmetric dimethylarginine accelerated endothelial cell senescence. Arterioscler Thromb Vasc Biol 24: 1816-1822, 2004.
30. Apostolovic S, Perisc Z, Cosic I and Tomasevic M: Oxidant stress after coronary stent implementation. Facta Universitatis Series. Med Biol 13: 78-83, 2007.
31. Bogle RG, MacAllister RJ, Whitley GS and Vallance P: Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 269: C750-C756, 1995.
32. Closs EI, Basha FZ, Habermeier A and Förstermann U: Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73, 1997.
33. Closs EI, Simon A, Vékony N and Rotmann A: Plasma membrane transporters for arginine. J Nutr 134: S2752-S2759, 2004.
34. Mann GE, Yudilevich DL and Sobrevia L: Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183-252, 2003.
35. Posch K, Schmidt K and Graier WF: Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide. Life Sci 64: 663-670, 1999.
36. Lee JH, Cook JR, Yang ZH, et al: PRMT7, a new protein arginine methyltransferase that synthetizes symmetric dimethylarginine. J Biol Chem 280: 3656-3664, 2005.
37. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS and Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 343: 209-214, 1999.